MX360001B - Compuestos de acrilamida como ligandos receptores de histamina h3. - Google Patents

Compuestos de acrilamida como ligandos receptores de histamina h3.

Info

Publication number
MX360001B
MX360001B MX2015000064A MX2015000064A MX360001B MX 360001 B MX360001 B MX 360001B MX 2015000064 A MX2015000064 A MX 2015000064A MX 2015000064 A MX2015000064 A MX 2015000064A MX 360001 B MX360001 B MX 360001B
Authority
MX
Mexico
Prior art keywords
histamine
receptor ligands
acrylamide compounds
compounds
formula
Prior art date
Application number
MX2015000064A
Other languages
English (en)
Other versions
MX2015000064A (es
Inventor
Venkateswarlu Jasti
Adi Reddy Dwarampudi
Ramakrishna Nirogi
Anil Karbhari Shinde
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2015000064A publication Critical patent/MX2015000064A/es
Publication of MX360001B publication Critical patent/MX360001B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Abstract

La presente invención se relaciona con compuestos novedosos de acrilamida de fórmula (I), y sus sales farmacéuticamente aceptables y el proceso para su preparación. (ver Fórmula) Los compuestos de fórmula (I) son útiles en el tratamiento de varios trastornos que se relacionan con receptores de histamina H3.
MX2015000064A 2012-08-23 2012-12-05 Compuestos de acrilamida como ligandos receptores de histamina h3. MX360001B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3464CH2012 2012-08-23
PCT/IN2012/000796 WO2014030170A1 (en) 2012-08-23 2012-12-05 Acrylamide compounds as histamine h3 receptor ligands

Publications (2)

Publication Number Publication Date
MX2015000064A MX2015000064A (es) 2015-04-08
MX360001B true MX360001B (es) 2018-10-18

Family

ID=54187093

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000064A MX360001B (es) 2012-08-23 2012-12-05 Compuestos de acrilamida como ligandos receptores de histamina h3.

Country Status (27)

Country Link
US (1) US9328092B2 (es)
EP (1) EP2888243B1 (es)
JP (1) JP5981654B2 (es)
KR (1) KR101707343B1 (es)
CN (1) CN104540812B (es)
AP (1) AP2014008139A0 (es)
AU (1) AU2012388383C1 (es)
BR (1) BR112015001524B1 (es)
CA (1) CA2878217C (es)
CY (1) CY1118035T1 (es)
DK (1) DK2888243T3 (es)
EA (1) EA025136B1 (es)
ES (1) ES2592819T3 (es)
HK (1) HK1204620A1 (es)
HR (1) HRP20161167T1 (es)
HU (1) HUE030901T2 (es)
IL (1) IL236437A (es)
LT (1) LT2888243T (es)
ME (1) ME02519B (es)
MX (1) MX360001B (es)
PL (1) PL2888243T3 (es)
PT (1) PT2888243T (es)
RS (1) RS55158B1 (es)
SG (1) SG11201408423XA (es)
SI (1) SI2888243T1 (es)
SM (1) SMT201600336B (es)
WO (1) WO2014030170A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11313246B2 (en) 2016-11-30 2022-04-26 General Electric Company Gas turbine engine wash system
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder
WO2023166351A1 (zh) * 2022-03-02 2023-09-07 杭州百诚医药科技股份有限公司 组胺h3受体抑制剂及其医药用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05013225A (es) * 2003-06-12 2006-03-09 Novo Nordisk As Derivados de 1-aril-4-(ariloxicarbonil)-piperazina para uso como inhibidores de la lipasa sensible a hormonas.
US8008301B2 (en) 2004-04-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
WO2005117865A1 (en) * 2004-06-02 2005-12-15 F. Hoffmann-La Roche Ag Naphthaline derivatives useful as histamine-3-receptor ligands
CN1972926B (zh) 2004-06-21 2011-02-16 霍夫曼-拉罗奇有限公司 作为组胺受体拮抗剂的吲哚衍生物
AU2005277518B2 (en) 2004-08-23 2011-08-04 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
KR101047204B1 (ko) * 2005-11-30 2011-07-06 에프. 호프만-라 로슈 아게 Ｈ3 조절제로서 사용하기 위한1,1-다이옥소-싸이오모폴린일 인돌일 메탄온 유도체
BRPI0711740A2 (pt) 2006-05-30 2011-12-06 Hoffmann La Roche compostos, processo para a sua manufatura,composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, método para o tratamento ou prevenção de obesidade, de diabetes do tipo ii, e uso dos compostos na manufatura de medicamentos
JP2010534217A (ja) * 2007-07-25 2010-11-04 エフ．ホフマン−ラ ロシュ アーゲー ベンゾフラン−及びベンゾ［ｂ］チオフェン−２−カルボン酸アミド誘導体ならびにヒスタミン３受容体モジュレータとしてのその使用
US20090170869A1 (en) 2007-09-06 2009-07-02 Desmond John Best Piperazine derivative having affinity for the histamine h3 receptor
WO2009100120A2 (en) 2008-02-04 2009-08-13 Neurogen Corporation Pyridinyl-substituted piperazinyl oxoethyl tetrahydropyrazolopyridines
WO2009121812A1 (en) 2008-03-31 2009-10-08 Evotec Neurosciences Gmbh Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
CN102015636B (zh) 2008-05-08 2014-08-13 埃沃特克股份有限公司 作为组胺h3受体拮抗剂的氮杂环丁烷类和环丁烷类化合物
WO2012029070A1 (en) * 2010-09-02 2012-03-08 Suven Life Sciences Limited Heterocyclyl compounds as histamine h3 receptor ligands

Also Published As

Publication number Publication date
AP2014008139A0 (en) 2014-12-31
HRP20161167T1 (hr) 2016-11-04
HK1204620A1 (en) 2015-11-27
CA2878217C (en) 2016-05-17
SG11201408423XA (en) 2015-01-29
CY1118035T1 (el) 2017-05-17
BR112015001524B1 (pt) 2022-04-05
HUE030901T2 (en) 2017-06-28
IL236437A0 (en) 2015-02-26
ES2592819T3 (es) 2016-12-01
NZ703323A (en) 2016-03-31
KR101707343B1 (ko) 2017-02-15
US9328092B2 (en) 2016-05-03
EP2888243A1 (en) 2015-07-01
LT2888243T (lt) 2016-10-10
IL236437A (en) 2016-12-29
EP2888243B1 (en) 2016-08-17
AU2012388383B2 (en) 2015-12-10
ME02519B (me) 2017-02-20
SI2888243T1 (sl) 2016-11-30
BR112015001524A2 (pt) 2017-07-04
PL2888243T3 (pl) 2017-01-31
RS55158B1 (sr) 2017-01-31
KR20150024918A (ko) 2015-03-09
JP2015526462A (ja) 2015-09-10
PT2888243T (pt) 2016-09-21
CN104540812B (zh) 2016-08-24
MX2015000064A (es) 2015-04-08
EA201590413A1 (ru) 2015-06-30
CN104540812A (zh) 2015-04-22
CA2878217A1 (en) 2014-02-27
EA025136B1 (ru) 2016-11-30
AU2012388383A1 (en) 2015-01-22
WO2014030170A1 (en) 2014-02-27
AU2012388383C1 (en) 2016-03-17
JP5981654B2 (ja) 2016-08-31
SMT201600336B (it) 2016-11-10
US20150218129A1 (en) 2015-08-06
DK2888243T3 (en) 2016-09-26

Similar Documents

Publication Publication Date Title
PH12015502615B1 (en) Chemical compounds
EA201391332A1 (ru) Лиганды опиоидных рецепторов и способы их применения и получения
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12015501920B1 (en) USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd RELATED DISORDERS
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
MX2014000779A (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide.
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
GEP201706690B (en) Novel process for making compounds for use in treatment of cancer
TN2015000120A1 (en) Oxazolidin-2-one-pyrimidine derivatives
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MX2014002832A (es) Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
EA201391056A1 (ru) Гетероарильные соединения в качестве лигандов 5-htрецептора
MX2016005759A (es) Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MX339858B (es) Compuestos novedosos como ligandos del receptor h3 de la histamina.
MX339460B (es) Derivados de benzazol como ligandos del receptor h4 de histamina.
TN2013000420A1 (en) 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors
TW201613884A (en) Selective NR2B antagonists
MX360001B (es) Compuestos de acrilamida como ligandos receptores de histamina h3.
EA201491878A8 (ru) Замещенные ксантиновые производные
MX2014003455A (es) Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide.
WO2013048949A3 (en) Selective nr2b antagonists
EA201390327A1 (ru) Гетероциклильные соединения в качестве лигандов гистаминовых hрецепторов
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
MX2018004256A (es) Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.
IN2013CH01199A (es)

Legal Events

Date Code Title Description
FG Grant or registration